Rx Propellant, a science and R&D platform backed by Actis and part of General Atlantic, will invest USD 100 million to develop a large-format life sciences campus in Genome Valley, Hyderabad.
Announced at the opening of BioAsia 2026, the project reflects Rx Propellant’s long-term commitment to strengthening India’s life sciences ecosystem. The campus will span over one million sq. ft. of advanced laboratory infrastructure, delivered in phases over six years, and will be the largest single, integrated life sciences campus in Genome Valley. Designed for corporations seeking scalable, high-quality R&D and allied infrastructure, it will provide institutional-grade laboratory spaces, fully compliant buildings, and high-performance electromechanical systems within a robust, resilient design.
Rx Propellant already has an established presence in Genome Valley with its one GV and three GV campuses fully leased to a mix of leading Indian and global life sciences companies. Beyond Hyderabad, the company is developing the Navi Mumbai Research District, a 16-acre site designed to be Mumbai’s largest cohesive ecosystem for science, research, and innovation.
